Juvenile Primary Fibromyalgia Syndrome Treatment & Management

  • Author: Angelo P Giardino, MD, PhD, MPH; Chief Editor: Lawrence K Jung, MD   more...
 
Updated: Nov 28, 2011
 

Approach Considerations

Because of the multifaceted problems that develop, effective treatment of fibromyalgia syndrome (FMS) requires a multidisciplinary approach, which may include medication, physical therapy, exercise, support groups, and psychological therapy. No surgical treatment is indicated. The goals of treatment are to reduce pain and depression, to decrease sleep disturbances, and to promote physical activity. A number of cognitive-behavioral interventions may help to mitigate the disorder. Activity is a mainstay in the treatment of FMS.

Go to Fibromyalgia and Rehabilitation and Fibromyalgia for complete information on these topics.

Next

Pharmacologic Therapy

The medication treatment for juvenile primary fibromyalgia syndrome (JPFS) is inferred for what has been studied and used in adult fibromyalgia. Typical medication regimens for pediatric FMS primarily include skeletal muscle relaxants, low-dose tricyclic antidepressants, and selective serotonin reuptake inhibitors (SSRIs). Some evidence reports that pain and symptom management with nonsteroidal anti-inflammatory drugs (NSAIDs) in combination with antidepressants and nonaddictive analgesics is effective.

Low-dose antidepressants, such as amitriptyline (Elavil), and skeletal muscle relaxants, such as cyclobenzaprine (Flexeril), help decrease the hyperarousal mechanisms in fibromyalgia and, in turn, help the child and adolescent sleep better. Both medications are administered at bedtime or 1-2 hours before bedtime. Some debate surrounds which medication should be initially used. Some suggest the use of cyclobenzaprine first in treatment, whereas others suggest beginning medication therapy with low-dose tricyclic antidepressants.[12]

An adult study found the combination of a low-dose tricyclic antidepressants (amitriptyline) and the SSRI fluoxetine (Prozac) to be effective in improving sleep quality and alleviating pain and fatigue.[17] A current level 3 clinical trial of fluoxetine to test its efficacy in treating JPFS is under way.

Depending on which medication is started first, either skeletal muscle relaxants or low-dose tricyclic antidepressants have been used when the child or adolescent does not respond to the initial medication. An NSAID or acetaminophen is used in conjunction with the muscle relaxants or antidepressants in some cases that are unresponsive to the mainstay therapies alone. Active investigation is underway to look at the potential role for S-adenosylmethionine (SAMe) and the SSRIs in the adult population.

A double-blind placebo controlled study of pregabalin in adults older than 18 years found reduction in pain intensity ratings as well as an improvement in reported sleep outcomes and an improvement in the quality of sleep.[18] In 2007, the US Food and Drug Administration (FDA) approved pregabalin for treatment of fibromyalgia in adults, and this drug became the first FDA-approved treatment for fibromyalgia.

Pregabalin monotherapy is used to treat pain and other fibromyalgia-related symptoms in adults. Evidence suggests that pregabalin improves daily function for some patients with fibromyalgia. The FDA states that the manufacturer of pregabalin (Pfizer) may conduct studies of pregabalin in children with fibromyalgia and in breast-feeding women, but such studies have not been completed at this time.

Bennett and Tayag-Kier et al suggested that a sleep analysis in children is helpful in determining treatable causes of sleep disturbance and periodic limb movement in sleep (PLMS).[2, 13] Few studies have involved children; however, low-dose tricyclic antidepressants or cyclobenzaprine has been used to help promote deeper sleep. Gedalia et al first tried cyclobenzaprine at bedtime to help promote sleep and then switched to low-dose antidepressants when 25% of the patients did not respond to the muscle relaxant.[12]

Previous
Next

Exercise and Activity

The goal of an exercise regime is to improve cardiovascular health and musculoskeletal fitness through nonimpact aerobic activity. An essential component of the treatment regimen, routine exercise consists of moderate exercise, such as brisk walking for 20 minutes 3 times per week and progression as tolerated. In 2000, Gedalia et al recommended physical therapy guidance to low-impact exercises, such as stretching, walking, biking, and swimming, for at least half an hour per day, to improve cardiovascular fitness.[12]

Returning to normal activity is imperative for the child who has stopped sport and social activities because of pain; this helps to modulate the pain. A physical therapist may be extremely helpful in establishing a reasonable exercise and activity regime. Maintaining the child’s physical conditioning is imperative for achieving the best possible long-term outcome of FMS.

The literature supports the therapeutic use of exercise and activity as an important treatment aspect of JPFS. A meta-analysis by Rossy et al found better outcomes with the use of cognitive-behavioral interventions (see Psychotherapy) and exercise than with medication.[19] Degotardi et al studied JPFS using exercise and a cognitive-behavioral approach and also found that cognitive-behavioral therapy strategies helped children effectively manage musculoskeletal pain associated with the disorder.[20]

One study evaluated 34 participants to determine whether physical activity was predictive of brain responses to experimental pain in FMS using functional magnetic resonance imaging (fMRI). Using self-reported measures of physical activity and fMRI of painful heat stimuli, the results found that greater physical activity was significantly associated with decreased pain ratings, suggesting that physically active FMS patients appear to maintain their ability to modulate pain while those who are less active do not.[21]

Previous
Next

Patient Support

Although a better understanding of what causes FMS would be helpful in determining treatment options, a holistic approach to the child and family living with this problem is the current recommendation.

Supporting the child and family to maintain as normal a lifestyle as possible is important because they live with a potentially chronic disorder. Emphasis on both the child’s and the family’s understanding of the disorder is helpful in learning to live with and overcome the problems. Attendance at school and other usual activities is imperative. Modifying participation or attendance may be necessary in light of the child’s ability to keep up with the expected activities.

Previous
Next

Psychotherapy

Cognitive-behavioral therapy has proven helpful in some cases. Conte et al compared children who had JPFS with healthy children and those who had arthritis.[14] The children and adolescents with JPFS showed increased levels of anxiety and depression, greater temperamental instability, higher pain sensitivity, and less family cohesion than healthy children or those with arthritis.

Degotardi et al studied 67 children with JPFS by using an educational and behavioral approach that addressed sleep difficulties, pain management, and exercise. They found significant differences in all physicals between preintervention status and postintervention status.[20]

Walco and Ilowite found that the use of a cognitive-behavioral program showed improvement in symptoms over a 4- to 24-month period.[22] Likewise, Vereker studied the use of counseling, behavioral techniques, and physical activity in 5 children who had shown improvement in symptoms.

Kashikar-Zuck et al found that children with JPFS had higher levels of depression than children with nonmalignant back pain, possibly because of the longer time taken for those with JPFS to receive specialty care and treatment for the problem.[23]

Previous
Next

Other Modalities

Other modalities found to be helpful in modulating pain include hypnotherapy and transcutaneous electrical nerve stimulation (TENS). Using palliative measures to treat symptoms and minimizing physical disability is an important treatment mainstay.

Previous
Next

Consultations

Because of the multifaceted symptoms that present, the patient may be referred to the following subspecialists for evaluation and treatment:

  • Physical medicine and rehabilitation specialist
  • Rheumatologist
  • Psychiatrist/psychologist
  • Pulmonary medicine specialist for evaluation of sleep disorders that may cause fatigue and the presence of PLMS
  • Orthopedist
Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Angelo P Giardino, MD, PhD, MPH  Associate Professor, Baylor College of Medicine; Chief Medical Officer, Texas Children's Health Plan; Chief Quality Officer, Medicine, Texas Children's Hospital

Angelo P Giardino, MD, PhD, MPH is a member of the following medical societies: Academic Pediatric Association, American Academy of Pediatrics, American Professional Society on the Abuse of Children, Harris County Medical Society, Helfer Society, and International Society for Prevention of Child Abuse and Neglect

Disclosure: Bayer Honoraria Review panel membership; Pfizer Grant/research funds Independent contractor; MedImmune Honoraria Review panel membership; Teva Pharmacutical travel & honoraria Managed Care Advisory Panel; CIGNA Honoraria Physician Advisory Council

Coauthor(s)

Eileen R Giardino, RN, MSN, PhD, FNP-BC, ANP-BC  Associate Professor of Nursing, Department of Acute and Continuing Care, University of Texas Health Sciences Center Houston School of Nursing

Eileen R Giardino, RN, MSN, PhD, FNP-BC, ANP-BC is a member of the following medical societies: American Academy of Nurse Practitioners, American College Health Association, American Nurses Association, American Professional Society on the Abuse of Children, and International Society for Prevention of Child Abuse and Neglect

Disclosure: Nothing to disclose.

Chief Editor

Lawrence K Jung, MD  Chief, Division of Pediatric Rheumatology, Children's National Medical Center

Lawrence K Jung, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Rheumatology, Clinical Immunology Society, and New York Academy of Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Herbert S Diamond, MD Adjunct Professor of Medicine, Division of Rheumatology, University of Pittsburgh School of Medicine; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, and Phi Beta Kappa

Disclosure: Merck Ownership interest Other; Smith Kline Ownership interest Other; Zimmer Ownership interest Other

Gregory F Keenan, MD, Director of Medical Affairs, Department of Immunology, Centocor, Inc

Gregory F Keenan, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Rheumatology

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Anthony KK, Schanberg LE. Juvenile primary fibromyalgia syndrome. Curr Rheumatol Rep. Apr 2001;3(2):165-71. [Medline].

  2. Bennett RM. The fibromyalgia syndrome. In: Textbook of Rheumatology. 5th ed. Philadelphia, PA: WB Saunders Co; 1997:511-9.

  3. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum. Jun 2008;37(6):339-52. [Medline].

  4. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum. Jun 2007;36(6):339-56. [Medline].

  5. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. Jan 1995;38(1):19-28. [Medline].

  6. Romano TJ. Fibromyalgia in children; diagnosis and treatment. W V Med J. Mar 1991;87(3):112-4. [Medline].

  7. Buskila D, Press J, Gedalia A. Assessment of nonarticular tenderness and prevalence of fibromyalgia in children. J Rheumatol. Feb 1993;20(2):368-70. [Medline].

  8. Kashikar-Zuck S, Graham TB, Huenefeld MD, Powers SW. A review of biobehavioral research in juvenile primary fibromyalgia syndrome. Arthritis Care Res. Dec 2000;13(6):388-97. [Medline].

  9. Yunus MB, Masi AT. Juvenile primary fibromyalgia syndrome. A clinical study of thirty-three patients and matched normal controls. Arthritis Rheum. Feb 1985;28(2):138-45. [Medline].

  10. Siegel DM, Janeway D, Baum J. Fibromyalgia syndrome in children and adolescents: clinical features at presentation and status at follow-up. Pediatrics. Mar 1998;101(3 Pt 1):377-82. [Medline].

  11. Buskila D, Neumann L, Hershman E. Fibromyalgia syndrome in children--an outcome study. J Rheumatol. Mar 1995;22(3):525-8. [Medline].

  12. Gedalia A, Garcia CO, Molina JF; Bradford NJ; Espinoza LR. Fibromyalgia syndrome: experience in a pediatric rheumatology clinic. Clin Exp Rheumatol. May-Jun 2000;18(3):415-9. [Medline].

  13. Tayag-Kier CE, Keenan GF, Scalzi LV. Sleep and periodic limb movement in sleep in juvenile fibromyalgia. Pediatrics. Nov 2000;106(5):E70. [Medline].

  14. Conte PM, Walco GA, Kimura Y. Temperament and stress response in children with juvenile primary fibromyalgia syndrome. Arthritis Rheum. Oct 2003;48(10):2923-30. [Medline].

  15. Neumann L, Smythe HA, Buskila D. Performance of point count and dolorimetry in assessing nonarticular tenderness in children. Arthritis and Rheumatism. 1989;28(2):138-145.

  16. Calabro JJ. Fibromyalgia (fibrositis) in children. Am J Med. Sep 29 1986;81(3A):57-9. [Medline].

  17. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. Nov 1996;39(11):1852-9. [Medline].

  18. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. Sep 2008;9(9):792-805. [Medline].

  19. Rossy LA, Buckelew SP, Dorr N, et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med. Spring 1999;21(2):180-91. [Medline].

  20. Degotardi PJ, Klass ES, Rosenberg BS, et al. Development and evaluation of a cognitive-behavioral intervention for juvenile fibromyalgia. J Pediatr Psychol. Aug 2006;31(7):714-23. [Medline].

  21. McLoughlin MJ, Stegner AJ, Cook DB. The relationship between physical activity and brain responses to pain in fibromyalgia. J Pain. Jun 2011;12(6):640-51. [Medline]. [Full Text].

  22. Walco GA, Ilowite NT. Cognitive-behavioral intervention for juvenile primary fibromyalgia syndrome. J Rheumatol. Oct 1992;19(10):1617-9. [Medline].

  23. Kashikar-Zuck S, Vaught MH, Goldschneider KR, et al. Depression, coping, and functional disability in juvenile primary fibromyalgia syndrome. J Pain. Oct 2002;3(5):412-9. [Medline].

Previous
Next
 
Illustration of 9 paired tender points identified in the 1990 statement of the American College of Rheumatology on fibromyalgia. They are as follows: (a) insertion of nuchal muscles into occiput, (b) upper border of trapezius, (c) muscle attachments to upper medial border of scapula, (d) anterior aspects of the C5–C7 intertransverse spaces, (e) second rib space 3 cm lateral to the sternal border, (f) muscle attachments to lateral epicondyle 2 cm below bony prominence, (g) upper outer quadrant of gluteal muscles, (h) muscle attachments just posterior to greater trochanter, and (i) medial fat pad of knee proximal to joint line.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.